Chularat Hospital PCL

As of June 30, 2026, Chularat Hospital PCL NVDR carries a market capitalization of 17.16B, placing it among publicly traded companies globally. Its enterprise value stands at 16.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chularat Hospital PCL NVDR's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Chularat Hospital PCL NVDR has 11.00B shares outstanding.

As of June 30, 2026, Chularat Hospital PCL NVDR trades at a trailing price-to-earnings ratio of 17.65. The price-to-sales ratio is 2.03, and the price-to-book ratio stands at 2.21.

As of June 30, 2026, Chularat Hospital PCL NVDR trades at an EV/EBITDA multiple of 9.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Chularat Hospital PCL NVDR trades at an EV/FCF ratio of 25.03, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 16.81B versus a market cap of 17.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chularat Hospital PCL NVDR maintains a current ratio of 2.81, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.79, indicating elevated leverage, while an interest coverage ratio of 77.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chularat Hospital PCL NVDR posted a return on equity (ROE) of 12.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.63 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.95, useful for judging operating efficiency across full business cycles. The company generates approximately 1.88M in revenue per employee across its workforce of 4,520.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.44 indicates how many times Chularat Hospital PCL NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chularat Hospital PCL NVDR recorded 258.09M in income tax expense. That works out to an effective tax rate of 20.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.27B, leaving 972.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Chularat Hospital PCL NVDR's stock has declined approximately 1.29% over the past 52 weeks. The 50-day moving average sits at 1.56, while the 200-day moving average is 1.52.

Over the twelve months ended June 30, 2026, Chularat Hospital PCL NVDR generated 8.48B in revenue and converted that into 972.80M in net income, yielding earnings per share of 0.09. EBITDA reached 1.79B, while operating income came in at 1.28B.

As of June 30, 2026, Chularat Hospital PCL NVDR holds 1.34B in cash and equivalents against 555.76M in total debt, resulting in a net debt position of -710.10M. Total book value stands at 7.75B, with working capital of 2.26B providing operational flexibility.

Chularat Hospital PCL NVDR produced 1.46B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -811.11M in capital expenditures, free cash flow totaled 653.34M - equivalent to 0.06 per share.

Over the twelve months ended June 30, 2026, Chularat Hospital PCL NVDR posted a gross margin of 28.43, reflecting its pricing power and cost economics. The operating margin of 15.08 and net profit margin of 11.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chularat Hospital PCL NVDR paid dividends of 0.07 per share. The dividend payout ratio of 73.49 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chularat Hospital PCL NVDR shareholders.

Chularat Hospital PCL NVDR's most recent stock split took place on May 11, 2015 with a 1:10 split ratio.

As of June 30, 2026, Chularat Hospital PCL NVDR has an Altman Z-Score of 7.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.